GlassScriptPhysician profile
Brittany Ea Hager
NPI 1285117903
$2,474.96
in general payments reported to CMS, 2019-2025
29 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $1,556 · 2023: $245 · 2024: $350 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625 · Education: $91.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.98 |
| Education | $91.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $706.65 | 2022 | |
| Abbvie INC. | $430.48 | 2021-2024 | |
| Sk Life Science, INC. | $152.06 | 2022 | |
| Janssen Biotech, INC. | $150.93 | 2023-2025 | Erleada, Akeega |
| Pfizer INC. | $131.07 | 2023-2024 | |
| Genentech USA, INC. | $90.59 | 2022 | |
| Sumitomo Pharma America, INC. | $82.64 | 2023-2024 | Orgovyx |
| Allergan, INC. | $64.72 | 2021-2022 | |
| Argenx US, INC. | $51.25 | 2022-2023 | Vyvgart |
| Ucb, INC. | $50.76 | 2021-2022 | |
| Cognoa, INC. | $50.04 | 2023 | Canvas Dx |
| Eisai INC. | $48.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.53 | 2021-2022 | |
| Greenwich Biosciences, INC. | $42.40 | 2021 | |
| Emd Serono, INC. | $41.19 | 2022-2023 | Mavenclad |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $35.89 | 2023-2024 | |
| Axonics, INC. | $33.80 | 2024 | Bulkamid, Axonics |
| Coloplast Corp | $29.48 | 2025 | |
| Lundbeck LLC | $27.67 | 2022 | |
| Neurelis, INC. | $27.28 | 2022 | |
| Merck Sharp & Dohme LLC | $27.27 | 2023 | Lynparza |
| Dendreon Pharmaceuticals LLC | $25.14 | 2024 | Provenge |
| Impel Pharmaceuticals INC. | $24.31 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.41 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.61 | 2023 | |
| Endo Pharmaceuticals INC. | $16.15 | 2024 | Xiaflex |
| Teva Pharmaceuticals USA, INC. | $14.23 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Hager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.